Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Etentamig + Nirogacestat |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Etentamig | TNB-383B|TNB383B|TNB 383B|ABBV383|ABBV 383|ABBV-383 | CD3 Antibody 119 TNFRSF17 Antibody 22 | Etentamig (ABBV-383) is a bispecific antibody that targets alpha CD3 and BCMA, potentially resulting in the activation of T-cells and tumor cell lysis (Journal of Clinical Oncology 2018 36:15_suppl, 8034-8034, PMID: 36029527). | |
| Nirogacestat | Ogsiveo | PF-03084014|PF 03084014|PF03084014 | Gamma secretase inhibitor 13 | Ogsiveo (nirogacestat) is a small molecule that selectively binds to Gamma-secretase and inhibits its proteolytic activity on downstream targets including NOTCH receptor proteins, thus blocking NOTCH pathway activation in cancer (PMID: 28887726, PMID: 31211955). Ogsiveo (nirogacestat) is FDA-approved for use in patients with progressing desmoid tumors (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|